Lilly Updates Open Letter Regarding the Use of Tirzepatide for Cosmetic Weight Loss
Eli Lilly continues to emphasize the potential harm that could come with using GLP-1 receptor agonists for off-label purposes.
October 24, 2026
Breaking News
Can an Office harassment lawyer negotiate a settlement? |
Why is Jack Bodenstein gaining attention? |
Which 100 Series Dash Mats offer the best fit and protection? |
Is oven repair Ottawa worth it for older electric and gas ovens? |
How often should organizations conduct a cloud penetration test? |
